Gene expression profiling of anticancer immune responses

Ena Wang, Monica C. Panelli, Vladia Monsurró, Francesco M. Marincola

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Anticancer immune responses can be enhanced by immune manipulation, however, the biological mechanism responsible for these immune responses remains largely unexplained. Conventional immunology researchers have extensively studied specific interactions between immune and cancer cells, and additional investigations have identified co-factors that may enhance the effectiveness of such interactions. As the molecular understanding of individual interactions increases, it is becoming apparent that no single mechanism can explain the phenomenon of tumor rejection. The contribution of several components of the innate and adaptive immune response is likely to be required for successful tumor rejection. These components may be variably recruited and activated by molecules with immune modulatory properties being produced by tumor and bystander cells within the tumor micro-environment. Such complexity can only be appreciated and solved by high-throughput tools capable of providing a global view of biological processes as they occur. This review will present selected examples of how high-throughput gene expression profiling may contribute to the understanding of anticancer immune responses. As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness.

Original languageEnglish
Pages (from-to)288-295
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume6
Issue number3
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Gene Expression Profiling
Neoplasms
Biological Phenomena
Adaptive Immunity
Allergy and Immunology
Innate Immunity
Research Personnel

Keywords

  • Human leukocyte antigen
  • IL-2 immunoresponsiveness
  • Polymorphism
  • T-cell

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Wang, E., Panelli, M. C., Monsurró, V., & Marincola, F. M. (2004). Gene expression profiling of anticancer immune responses. Current Opinion in Molecular Therapeutics, 6(3), 288-295.

Gene expression profiling of anticancer immune responses. / Wang, Ena; Panelli, Monica C.; Monsurró, Vladia; Marincola, Francesco M.

In: Current Opinion in Molecular Therapeutics, Vol. 6, No. 3, 06.2004, p. 288-295.

Research output: Contribution to journalReview article

Wang, E, Panelli, MC, Monsurró, V & Marincola, FM 2004, 'Gene expression profiling of anticancer immune responses', Current Opinion in Molecular Therapeutics, vol. 6, no. 3, pp. 288-295.
Wang, Ena ; Panelli, Monica C. ; Monsurró, Vladia ; Marincola, Francesco M. / Gene expression profiling of anticancer immune responses. In: Current Opinion in Molecular Therapeutics. 2004 ; Vol. 6, No. 3. pp. 288-295.
@article{2fcb348545574c05bdf34703457fdfe4,
title = "Gene expression profiling of anticancer immune responses",
abstract = "Anticancer immune responses can be enhanced by immune manipulation, however, the biological mechanism responsible for these immune responses remains largely unexplained. Conventional immunology researchers have extensively studied specific interactions between immune and cancer cells, and additional investigations have identified co-factors that may enhance the effectiveness of such interactions. As the molecular understanding of individual interactions increases, it is becoming apparent that no single mechanism can explain the phenomenon of tumor rejection. The contribution of several components of the innate and adaptive immune response is likely to be required for successful tumor rejection. These components may be variably recruited and activated by molecules with immune modulatory properties being produced by tumor and bystander cells within the tumor micro-environment. Such complexity can only be appreciated and solved by high-throughput tools capable of providing a global view of biological processes as they occur. This review will present selected examples of how high-throughput gene expression profiling may contribute to the understanding of anticancer immune responses. As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness.",
keywords = "Human leukocyte antigen, IL-2 immunoresponsiveness, Polymorphism, T-cell",
author = "Ena Wang and Panelli, {Monica C.} and Vladia Monsurr{\'o} and Marincola, {Francesco M.}",
year = "2004",
month = "6",
language = "English",
volume = "6",
pages = "288--295",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "3",

}

TY - JOUR

T1 - Gene expression profiling of anticancer immune responses

AU - Wang, Ena

AU - Panelli, Monica C.

AU - Monsurró, Vladia

AU - Marincola, Francesco M.

PY - 2004/6

Y1 - 2004/6

N2 - Anticancer immune responses can be enhanced by immune manipulation, however, the biological mechanism responsible for these immune responses remains largely unexplained. Conventional immunology researchers have extensively studied specific interactions between immune and cancer cells, and additional investigations have identified co-factors that may enhance the effectiveness of such interactions. As the molecular understanding of individual interactions increases, it is becoming apparent that no single mechanism can explain the phenomenon of tumor rejection. The contribution of several components of the innate and adaptive immune response is likely to be required for successful tumor rejection. These components may be variably recruited and activated by molecules with immune modulatory properties being produced by tumor and bystander cells within the tumor micro-environment. Such complexity can only be appreciated and solved by high-throughput tools capable of providing a global view of biological processes as they occur. This review will present selected examples of how high-throughput gene expression profiling may contribute to the understanding of anticancer immune responses. As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness.

AB - Anticancer immune responses can be enhanced by immune manipulation, however, the biological mechanism responsible for these immune responses remains largely unexplained. Conventional immunology researchers have extensively studied specific interactions between immune and cancer cells, and additional investigations have identified co-factors that may enhance the effectiveness of such interactions. As the molecular understanding of individual interactions increases, it is becoming apparent that no single mechanism can explain the phenomenon of tumor rejection. The contribution of several components of the innate and adaptive immune response is likely to be required for successful tumor rejection. These components may be variably recruited and activated by molecules with immune modulatory properties being produced by tumor and bystander cells within the tumor micro-environment. Such complexity can only be appreciated and solved by high-throughput tools capable of providing a global view of biological processes as they occur. This review will present selected examples of how high-throughput gene expression profiling may contribute to the understanding of anticancer immune responses. As reviews on technological aspects of the genomic analysis of cancer are already available, this review will provide a speculative discussion about their potential usefulness.

KW - Human leukocyte antigen

KW - IL-2 immunoresponsiveness

KW - Polymorphism

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=3242887932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242887932&partnerID=8YFLogxK

M3 - Review article

C2 - 15264431

AN - SCOPUS:3242887932

VL - 6

SP - 288

EP - 295

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 3

ER -